Clinical Trials in AML
Phase III Clinical Trial in GIST
In the News
Rog is the Hindi noun meaning ‘disease’. The addition of the prefix ‘a’ changes it to ‘without disease’ a fitting name for our company aiming to bring cures to cancers with a high unmet need.
AROG Pharmaceuticals is a privately held, late-stage biopharmaceutical company. At AROG Pharmaceuticals we are focused on developing treatments for people with cancer where there have been little to no advances in the last 20 years.
AROG Pharmaceuticals is based in Dallas, Texas, and was founded on March 29, 2010. We base our approach on two principles: improving the lives of cancer patients and focusing on indications with high unmet need.
Arog obtained exclusive worldwide rights to several patented benzimidazole-based compounds from Pfizer in April 2010. AROG pharmaceuticals has conducted several clinical trials with crenolanib in acute myeloid leukemia with FLT3 mutations in newly diagnosed or relapsed/refractory (R/R) patient populations; as well as a variety of solid tumors including R/R gastric cancer, gastrointestinal stromal tumors (GIST), and glioblastoma.
AROG has obtained Orphan Drug Designation Status in the following indications:
Malignant Glioma: December 20, 2010 - FDA
Soft Tissue Sarcoma: March 18, 2011 - FDA October 14, 2016 - EMA
Acute Myelogenous Leukemia: October 31, 2012 – FDA October 14, 2016 - EMA
AROG is based in Dallas, Texas and was founded in early 2010 when it obtained exclusive worldwide rights to a number of patented benzimidazole-based compounds, of which crenolanib was the lead.
To date, AROG has evaluated crenolanib across 16 Phase I-III trials in hundreds of patients, demonstrating clinical benefit and safety in multiple indications.
We have assembled an experienced and talented group of leaders to execute our vision.